Aspira Women's Health Announces Appointment of Ellen Beausang to the Board of Directors
Aspira Women's Health (NASDAQ:AWH) has announced the appointment of Ellen Beausang to its Board of Directors, effective February 10, 2025. Beausang, who currently serves as Chief Commercial Officer at BioReference Health, brings extensive experience in commercial strategy development within the diagnostics sector. The appointment comes at what the company describes as a commercial inflection point, as it focuses on growing existing business lines and developing new diagnostic tests to expand market opportunities.
Beausang's background includes over 5 years at BioReference Health and previous executive positions at major healthcare companies including Pfizer, Thermo Fisher Diagnostics, and Quest Diagnostics. CEO Michael Buhle highlighted her expertise as valuable for accelerating business growth and advancing the company's mission in women's healthcare.
Aspira Women's Health (NASDAQ:AWH) ha annunciato la nomina di Ellen Beausang nel suo Consiglio di Amministrazione, con effetto dal 10 febbraio 2025. Beausang, attualmente Chief Commercial Officer di BioReference Health, porta con sé una vasta esperienza nello sviluppo di strategie commerciali nel settore della diagnostica. La nomina avviene in quello che l'azienda descrive come un punto di inflessione commerciale, poiché si concentra sulla crescita delle linee di business esistenti e sullo sviluppo di nuovi test diagnostici per ampliare le opportunità di mercato.
Il background di Beausang include oltre 5 anni trascorsi in BioReference Health e precedenti posizioni dirigenziali in importanti aziende sanitarie, tra cui Pfizer, Thermo Fisher Diagnostics e Quest Diagnostics. Il CEO Michael Buhle ha sottolineato come la sua esperienza sia preziosa per accelerare la crescita aziendale e promuovere la missione dell'azienda nella salute delle donne.
Aspira Women's Health (NASDAQ:AWH) ha anunciado el nombramiento de Ellen Beausang en su Junta Directiva, con efecto a partir del 10 de febrero de 2025. Beausang, quien actualmente se desempeña como Directora Comercial en BioReference Health, aporta una amplia experiencia en el desarrollo de estrategias comerciales dentro del sector de diagnósticos. La designación se produce en lo que la compañía describe como un punto de inflexión comercial, ya que se enfoca en hacer crecer las líneas de negocio existentes y en desarrollar nuevas pruebas diagnósticas para expandir las oportunidades de mercado.
El historial de Beausang incluye más de 5 años en BioReference Health y posiciones ejecutivas previas en importantes empresas de salud, incluyendo Pfizer, Thermo Fisher Diagnostics y Quest Diagnostics. El CEO Michael Buhle destacó su experiencia como valiosa para acelerar el crecimiento empresarial y avanzar en la misión de la empresa en el cuidado de la salud de las mujeres.
Aspira Women's Health (NASDAQ:AWH)는 Ellen Beausang을 이사회에 임명한다고 발표했으며, 이사의 직무는 2025년 2월 10일부터 시작된다. 현재 BioReference Health의 최고 상업 책임자(COO)로 활동 중인 Beausang은 진단 분야에서 상업 전략 개발에 대한 광범위한 경험을 가지고 있다. 이 임명은 회사가 기존 비즈니스 라인의 성장 및 새로운 진단 테스트 개발에 집중하는 상업적 전환점에 접어들고 있다고 설명하고 있다.
Beausang의 경력은 BioReference Health에서의 5년 이상과 Pfizer, Thermo Fisher Diagnostics 및 Quest Diagnostics와 같은 주요 헬스케어 기업에서의 경영진 직책을 포함한다. CEO Michael Buhle는 그녀의 전문성이 비즈니스 성장을 가속화하고 여성 건강 분야에서 회사를 발전시키는 데 있어 귀중하다고 강조했다.
Aspira Women's Health (NASDAQ:AWH) a annoncé la nomination de Ellen Beausang au sein de son Conseil d'administration, prenant effet le 10 février 2025. Beausang, qui est actuellement Directrice Commerciale chez BioReference Health, apporte une vaste expérience dans le développement de stratégies commerciales dans le secteur des diagnostics. Cette nomination intervient à un moment que l'entreprise décrit comme un tournant commercial, alors qu'elle se concentre sur la croissance des lignes de produits existantes et le développement de nouveaux tests diagnostiques pour élargir les opportunités de marché.
Le parcours de Beausang comprend plus de 5 ans chez BioReference Health ainsi que des postes exécutifs précédents dans d'importantes entreprises de santé telles que Pfizer, Thermo Fisher Diagnostics et Quest Diagnostics. Le PDG Michael Buhle a souligné que son expertise serait précieuse pour accélérer la croissance de l'entreprise et faire avancer la mission de l'entreprise dans le domaine de la santé des femmes.
Aspira Women's Health (NASDAQ:AWH) hat die Ernennung von Ellen Beausang in den Vorstand bekannt gegeben, die am 10. Februar 2025 wirksam wird. Beausang, die derzeit als Chief Commercial Officer bei BioReference Health tätig ist, bringt umfassende Erfahrung in der Entwicklung kommerzieller Strategien im Diagnosesektor mit. Die Ernennung erfolgt zu einem Zeitpunkt, den das Unternehmen als kommerziellen Wendepunkt bezeichnet, da es sich auf das Wachstum bestehender Geschäftsbereiche und die Entwicklung neuer diagnostischer Tests konzentriert, um Marktchancen zu erweitern.
Beausangs beruflicher Werdegang umfasst über 5 Jahre bei BioReference Health sowie frühere Führungspositionen in großen Gesundheitsunternehmen wie Pfizer, Thermo Fisher Diagnostics und Quest Diagnostics. CEO Michael Buhle hob hervor, dass ihre Expertise wertvoll sei, um das Unternehmenswachstum zu beschleunigen und die Mission des Unternehmens im Bereich der Frauen-Gesundheitsversorgung voranzutreiben.
- Addition of experienced diagnostics industry executive with proven commercial strategy expertise
- Strategic timing of appointment coinciding with commercial expansion phase
- None.
AUSTIN, TX / ACCESS Newswire / February 11, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Ellen Beausang to the Board of Directors, effective February 10, 2025.
"We are pleased to welcome Ellen Beausang to the Board of Directors," said Michael Buhle, Chief Executive Officer of Aspira Women's Health. "Ellen brings an extensive track record of developing and executing successful commercial strategies in the diagnostics space to our company, which is entering an exciting commercial inflection point as we grow our current business lines while developing new tests to expand our market opportunity. Her expertise will be invaluable to Aspira Women's Health as we accelerate the growth of our business and pursue our mission to bring much-needed changes to women's healthcare."
Ms. Beausang has been in an executive role at BioReference Health, a leading provider of innovative and tailored laboratory test solutions, for over 5 years, holding the role of Chief Commercial Officer since 2022. Prior to this, Ms. Beausang held executive roles of increasing responsibility at leading pharmaceutical and diagnostic companies including Pfizer, Thermo Fisher Diagnostics, and Quest Diagnostics.
About Aspira Women's Health Inc.
Aspira Women's Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.
OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer risk for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of
Our in-development test pipeline will expand our ovarian cancer portfolio and address the tremendous need for non-invasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, we intend to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, we have developed the first-ever non-invasive test designed to identify endometriomas, one of the most commonly occurring forms of severe endometriosis. Through our ongoing endometriosis development program, we are combining microRNA and protein biomarkers with patient data, with the intent of identifying all endometriosis independent of disease location or severity.
Forward-Looking Statements
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve a number of risks and uncertainties. Such forward-looking statements include statements regarding, among other things, the timing and completion of any products in the development pipeline and other statements that are predictive in nature, and whether the marketing of the OvaSuite portfolio will prove successful. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "designed to," "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," and other words of similar meaning and the use of future dates. These and additional risks and uncertainties are described more fully in the Company's filings with the SEC, including those factors identified as "Risk Factors" in our most recent Annual Report on Form 10-K, for the fiscal year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Aspira presently does not know, or that Aspira currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Aspira's expectations, plans, or forecasts of future events and views as of the date of this press release. Subsequent events and developments may cause the Company's assessments to change. However, while Aspira may elect to update these forward-looking statements at some point in the future, Aspira expressly disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Aspira's assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor Relations Contact:
Mike Cavanaugh
ICR Healthcare
mike.cavanaugh@icrhealthcare.com
SOURCE: Aspira Women's Health
View the original press release on ACCESS Newswire
FAQ
When did Ellen Beausang join Aspira Women's Health (AWH) Board of Directors?
What is Ellen Beausang's current role outside of AWH's board position?
What previous companies has AWH's new board member Ellen Beausang worked for?
How does Ellen Beausang's appointment align with AWH's current business strategy?
